Regulatory milestones

Amarin Corp. plc (NASDAQ:AMRN) was off $0.48 to $6.29 last week after FDA told the company that an advisory committee will meet on Oct. 16 to discuss an sNDA for hypertriglyceridemia drug Vascepa icosapent ethyl. The company is seeking to expand the label to include treatment of adults with high triglycerides with mixed dyslipidemia. The PDUFA date is Dec. 20. Amarin markets Vascepa in the U.S. as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia.

-- Samantha McGirr/p>